Greenwich Lifesciences Q1 net loss more than doubled to $5.66 million; R&D expenses rise 129% to $5.21 million

Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

GLSI

0.00
  • Greenwich Lifesciences posted a wider net loss of $5.7 million for the quarter ended March 31, 2026, versus $2.7 million a year earlier.
  • Research and development expense more than doubled, rising 129% to $5.21 million, primarily due to higher accounts payable for clinical trial expenses.
  • General and administrative costs edged up 4% to $518,190.
  • Net cash used in operating activities climbed to $4.7 million from $1.83 million.
  • Cash rose to $10.51 million as of March 31, 2026, helped by ATM stock sales that generated $9.03 million in net proceeds.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-027150), on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.